Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

SGB 1534

Known as: SGB-1534 
 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Quinazolines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1993
1993
Studies on quinazolines. 5. 2,3-dihydroimidazo[1,2-c]quinazoline derivatives: a novel class of potent and selective alpha 1-adrenoceptor antagonists and antihypertensive agents.
A series of 2-[(substituted phenylpiperazin-1-yl)methyl]- and 2-[(substituted phenylpiperidin-1-yl)methyl]-2,3-dihydroimidazo[1,2… Expand
Is this relevant?
1990
1990
Effects of a novel alpha 1-adrenoceptor antagonist, SGB-1534, on adrenergically induced renal vasoconstriction in dogs.
The alpha 1-adrenoceptor antagonistic effect of SGB-1534, a novel phenylpiperazine derivative, was examined in the renal vascular… Expand
Is this relevant?
1989
1989
Alpha-blocking potencies of antihypertensive agents (prazosin, terazosin, bunazosin, SGB-1534 and ketanserin) having with quinazoline or quinazolinedione as assessed by radioligand binding assay…
The comparative effects of antihypertensive agents, quinazoline or quinazolinedione residues (prazosin, bunazosin, terazosin, SGB… Expand
Is this relevant?
1989
1989
In vivo experiments for the evaluation of alpha 1-adrenoceptor antagonistic effects of SGB-1534 on canine urethra.
The alpha 1-adrenoceptor blocking effects of SGB-1534 on the urethral smooth muscle were compared in in vivo lower urinary tract… Expand
Is this relevant?
1988
1988
[Effects of prazosin, SGB-1534, dobutamine and isoproterenol on congestive heart failure in dogs].
Effects of prazosin, dobutamine, isoproterenol and SGB-1534, a new alpha-blockade, on congestive heart failure (CHF) in dogs were… Expand
Is this relevant?
1986
1986
Effects of a new antihypertensive agent, SGB-1534, on rat platelet aggregation.
The present study was designed to examine the antiplatelet activity of SGB-1534, 3-[2-[4-(o-methoxyphenyl)-1-piperazinyl]ethyl]-2… Expand
Is this relevant?
1986
1986
Further evaluation of the selectivity of a novel antihypertensive agent, SGB-1534, for peripheral alpha 1-adrenoceptors in the spinally anesthetized dog.
Experiments were designed to examine some characteristics of an orally active antihypertensive agent, SGB-1534 on alpha… Expand
Is this relevant?
1986
1986
Potent alpha-adrenoceptor blocking action of SGB-1534, a new quinazoline antihypertensive agent in vitro experiments.
SGB-1534 inhibited the contractile response to norepinephrine (NE), methoxamine (MO) and electrical transmural stimulation in the… Expand
Is this relevant?
1985
1985
Antihypertensive effects of a novel phenylpiperazine derivative, SGB-1534, on several hypertensive models of rats.
The antihypertensive activities of SGB-1534, 3-[2-[4-(o-methoxyphenyl)-1-piperazinyl]ethyl]-2,4 (1H,3H)-quinazolinedione… Expand
Is this relevant?
1985
1985
Cardiovascular effects of a novel antihypertensive agent, SGB-1534, in miniature pigs.
The cardiovascular effects of SGB-1534 (3-[2-[4-(o-methoxyphenyl)-1-piperazinyl]-2,4(1H,3H)-quinazolinedione monohydrochloride… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE